Eagle Pharmaceuticals Reports Third Quarter 2020 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Eagle Pharmaceuticals (EGRX) Tops Q3 EPS by 89c
November 2, 2020 6:49 AM ESTEagle Pharmaceuticals (NASDAQ: EGRX) reported Q3 EPS of $1.17, $0.89 better than the analyst estimate of $0.28. Revenue for the quarter came in at $49.9 million versus the consensus estimate of $47.02 million.
2020 Expense Guidance:
R&D expense in 2020, on a non-GAAP... More